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Abstract 
Objectives  
Current British guidelines advocate the use of risk prediction scores such as Thoracoscore to 
estimate mortality prior to radical surgery for non-small cell lung cancer (NSCLC). A recent 
publication used the National Lung Cancer Audit (NLCA) to produce a score to predict 90 day 
mortality (NLCA score).  The aim of this study is to validate the NLCA score, and compare its 
performance with Thoracoscore. 
Materials and Methods 
We performed an internal validation using 2858 surgical patients from NLCA and an external 
validation using 3191 surgical patients from the Danish Lung Cancer Registry (DLCR).  We 
calculated the proportion that died within 90 days of surgery. The discriminatory power of 
both scores was assessed by a receiver operating characteristic (ROC) and an area under the 
curve (AUC) calculation. 
Results  
Ninety day mortality was 5% in both groups. AUC values for internal and external validation 
of NLCA score and validation of Thoracoscore were 0.68 (95% CI 0.63-0.72), 0.60 (95% CI 
0.56-0.65) and 0.60 (95% CI 0.54-0.66) respectively.  Post-hoc analysis was performed using 
NLCA records on 15554 surgical patients to derive summary tables for 30 and 90 day 
mortality, stratified by procedure type, age and performance status.  
Conclusions 
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Neither score performs well enough to be advocated for individual risk stratification prior to 
lung cancer surgery. It may be that additional physiological parameters are required; 
however this is a further project. In the interim we propose the use of our summary tables 
that provide the real-life range of mortality for lobectomy and pneumonectomy. 
Keywords: 
Lung cancer 
Thoracic surgery 
Mortality 
Validation study 
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1 Introduction 
Current British Thoracic Society (BTS) guidelines advocate the use of a risk prediction score 
such as Thoracoscore to estimate, prior to surgery, the risk of death following radical 
surgical management in those with non-small cell lung cancer (NSCLC).(1) However, 
Thoracoscore was developed to predict in-hospital mortality only and was not derived from 
a population with solely malignant disease but included patients undergoing thoracic 
surgery for a range of indications from the relatively minor spontaneous pneumothorax to 
complicated pneumonectomy for lung cancer. Recent work has suggested that using in-
hospital or 30 day mortality may underestimate the risk of early death following surgery for 
lung cancer.(2, 3) In addition, two studies have tried to validate Thoracoscore, but found it 
to be of limited discriminative ability to predict mortality in lung cancer patients.(4, 5) 
Despite this some surgical centres in the United Kingdom (UK) use this score routinely pre-
surgery to provide an estimation of risk.  Powell et al(6) used the National Lung Cancer Audit 
(NLCA) linked to Hospital Episode Statistics (HES) to produce a new score to predict 90 day 
mortality after surgery in those with lung cancer. The aim of the present study is to validate 
this score, henceforth called the NLCA score, and compare its performance with 
Thoracoscore in patients with lung cancer using an updated NLCA dataset and the Danish 
Lung Cancer Registry (DLCR). 
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2 Methods 
2.1 Internal validation 
2.1.1 Patient population and data source 
The NLCA is a prospective database which has collated information provided by 157 English 
NHS hospitals on demographic, tumour and treatment for patients with primary lung cancer 
since 2004. It is linked to data from Hospital Episode Statistics (HES), used to derive co-
morbidity information from coded inpatient episodes alongside information regarding 
interventions and procedures performed, and Office of National Statistics (ONS) which 
provides information on date of death. 
We identified patients from NLCA data who underwent curative surgery for NSCLC (using 
Office of Population Censuses and Surveys Classification of Interventions (OPCS-4) coding) 
between 1st January 2004 and 31st March 2012. Those with stage 3b or stage 4 lung cancer 
were excluded, as were those with International Classification of Diseases- revision 10(ICD-
10) codes for metastases recorded prior to the procedure date. The original predictive score 
was derived from NLCA patient data for operations performed between 1st January 2004 
and 31st March 2010 so we limited our internal validation cohort to those who underwent 
surgery between 1st April 2010 and 31st March 2012 to ensure that this was an independent 
population. 
2.2 External validation 
2.2.1 Data source and patient population 
The Danish Lung Cancer Registry (DLCR) contains data on over 90% of patients diagnosed 
with lung cancer in Denmark from 2005 onwards. Registry data are linked with data from 
national databases: demographic information is retrieved from the Central Population 
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Register, pathology information from the National Pathology Registry and comorbidity data 
from the National Hospital Register. 
All patients who underwent curative surgery for NSCLC between 2005 and 2011 were 
identified from the DLCR to form our external validation cohort. 
2.3 Covariates 
For the purposes of validation procedure type was classified as pneumonectomy, bi-
lobectomy/lobectomy/wedge/segmentectomy, or other. Where there were multiple 
procedure codes for an individual the most extensive procedure type was included; the 
most recent procedure date was included if there was more than one for any individual. 
Comorbidity was classified according to Charlson index using our established methods.(7-9) 
Patients were then categorised into two groups based on their Charlson index (0-1 and ≥ 2). 
Percentage predicted forced expiratory volume in 1 second (FEV1) was categorised into four 
groups (>80%, 61-80%, 40-60% and <40%) and WHO performance status into three groups 
(PS: 0, 1-2, ≥3). Pre-treatment records in NLCA and DLCR records linked to National 
Pathology Registry were used for stage (grouped as IA, IB, IIA/IIB and IIIA) according to the 
7th edition of UICC TNM, with post-treatment stage used if pre-treatment records were 
missing. Age was categorised into four groups (<55, 55-65, 66-85 and >75). Those with 
missing data from any of the covariates listed were excluded from the validation. 
2.4 Statistical analysis 
All statistical analyses were conducted using Stata MP V.12 (StataCorp, Texas, USA). All 
patients in the NLCA and DLCR datasets were assigned a risk score using the coefficients and 
constants from the multivariable model in the NLCA score (6) using the equation: risk score 
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= constant + sum of β coefficients at different values of each covariate. We then identified 
those who died within 90 days of surgery.  
The NLCA dataset only was then used to assign each patient a risk score based on 
Thoracoscore in the same way using the β coefficients and constant derived for 
Thoracoscore.(10) Since the NLCA dataset does not contain fields for American Society of 
Anesthesiologists (ASA) score or Medical Research Council (MRC) dyspnoea score which are 
required to generate Thoracoscore, we used data that were available to estimate these 
scores for the purposes of validation as follows; patients are given a coefficient in 
Thoracoscore if their ASA grade is ≥ 3; which refers to severe systemic disturbance from any 
cause. It is not possible to state an absolute measure of severity, as this is a matter of 
clinical judgement. We therefore used a combination of Charlson co-morbidity score and 
performance status (as a measure of functional capacity) to derive the ASA grade. Those 
with a Charlson score of ≥ 2 and performance status ≥ 2 were given an ASA grade of 3 for 
the purposes of this analysis. Patients with MRC dyspnoea score of ≥ 3 are allocated a 
coefficient in Thoracoscore. This refers to those with some limitation of activity due to 
breathlessness during daily life. Those who had FEV1 < 60% predicted were assigned MRC 
dyspnoea score of ≥ 3. A sensitivity analysis was performed using various thresholds of 
Charlson score, performance status and FEV1 to assign MRC dyspnoea score and ASA grade 
to the population, all of which produced very similar results in the validation. Once we had 
assigned all patients a coefficient for all covariates we identified all those who died in 
hospital (date of death prior to or the same as discharge date for their surgical procedure).  
The discriminatory power of each score to predict mortality was assessed by means of a 
receiver operating characteristic (ROC) curve and an area under the curve (AUC) calculation. 
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We also repeated the validation in the NLCA dataset using multiple imputation to create 
substituted values for the missing data fields for FEV1, performance status and stage.  
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3 Results 
3.1 NLCA patients 
We identified 17687 patients in the NLCA who received curative surgery for NSCLC between 
1st January 2004 and 31st March 2012. Of these we excluded 670 patients who had an ICD-
10 code for metastases prior to their operation date, 612 patients who had missing or 
incongruous diagnosis dates and 851 in whom the procedure date was >3 months before or 
>6 months after the NLCA diagnosis date. This left 15554 patients of which 6080 had a 
procedure date between 1st April 2010 and 31st March 2012.  We excluded a further 3222 
with incomplete data on FEV1, missing performance status or missing stage, leaving a final 
validation cohort of 2858 patients.  
3.2 Multiple imputation 
Due to the amount of missing data in the NLCA we performed multiple imputation to create 
substituted values for the missing variables. We performed the analysis with the entire 6080 
patients using the imputed values for FEV1, performance status and stage, where these 
were missing. There was minimal change in the area under the ROC curve, so the results of 
the original validation, restricted to those with complete data are reported. 
3.3 DLCR patients 
Our DLCR cohort comprised 4234 patients who underwent curative surgery from 2005 
onwards. We excluded 1043 patients with missing data on FEV1, performance status or 
stage, giving a validation cohort of 3191 patients. 
3.4 Demographic features 
Those in the NLCA validation cohort were older than those in DLCR, with a median age of 69 
years (interquartile range (IQR) 63-75 years) versus 66 years (interquartile range (IQR) 60-73 
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years) in the DLCR. There were proportionally more women in the DLCR group (49% versus 
46%) and their cohort also had a greater proportion of patients who were classified as WHO 
performance status 0 (54% compared with 43%). Pneumonectomy was infrequent in both 
groups with 9% of those in DLCR and 8% in NLCA undergoing that procedure. Despite these 
differences, both groups had a similar 90 day mortality of 5% (288 patients died within 90 
days of surgery in NLCA and 204 patients in DLCR overall). Features of the NLCA and DLCR 
groups are summarised in table 1. 
3.5 Validation of NLCA score 
The ROC curve generated from the application of the NLCA score to the NLCA validation 
cohort is shown in figure 1 (internal validation) and application to the DLCR cohort in figure 
2 (external validation). Area under the ROC curve was 0.68 (95% confidence interval (CI) 
0.63-0.72) and 0.60 (95% CI 0.56-0.65) respectively. 
3.6 Validation of Thoracoscore 
When the coefficients derived from Thoracoscore were used to compute risk probability 
scores in the NLCA validation cohort the area under the curve was 0.60 (95% CI 0.54-0.66). 
The ROC curve is presented in figure 3.  
3.7 Post-hoc analysis: Summary tables 
Neither Thoracoscore nor the NLCA score performed well enough to be advocated for 
routine use to predict surgical mortality in lung cancer patients. In the work by Powell et 
al(6) age, procedure type and performance status were identified as the major drivers of 
post-operative mortality. We therefore performed a post hoc analysis using data from the 
NLCA on all 15554 patients who underwent curative surgery for NSCLC between 1st January 
2004 and 31st March 2012 to derive summary tables for 30 and 90 day mortality, stratified 
 
 
10 
 
by procedure type, age and performance status. We excluded those sub groups which 
contained fewer than 50 patients as we were unable to provide accurate estimations of 
mortality due to the small numbers. Results for 30 day mortality are summarised in table 2 
and for 90 day in table 3. In general, these show increasing risks of mortality with increasing 
age and worsening performance status regardless of procedure type, however those 
undergoing pneumonectomy have higher predicted post-operative mortality than the 
lobectomy group for each age and performance status sub group.  
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Discussion 
We used two independent datasets to compare the performance of the recently derived 
NLCA score (6) with the currently recommended scoring system (Thoracoscore) for 
predicting early mortality after lung cancer surgery. There are several scales which are used 
for AUC value interpretation but, in general, ROC curves with an AUC < 0.75 are not 
considered to be clinically useful. Our results suggest therefore, that neither of these scoring 
systems has sufficient predictive or discriminative ability to be advocated for use in 
predicting risk of mortality for individual patients prior to surgery for NSCLC.  
3.8 Strengths and limitations 
The strength of this study is that we were able to perform both an internal and external 
validation using large UK and non-UK lung cancer populations to fully explore the 
performance of these risk scoring systems. The NLCA has previously been shown to be 
representative of the UK lung cancer population (11) and likewise the DLCR contains high 
quality data (12). However both datasets are made up of a predominantly white population 
so extrapolation of these results to different ethnic groups is difficult. 
Although data completeness is improving in the NLCA, missing data are still a challenge. A 
substantial proportion of patients do not have data on FEV1 (49% in our validation cohort). 
This is likely to represent data that were unavailable to the administrators at the time of 
data entry as all patients will have had some measure of their lung function performed prior 
to undergoing surgical resection. Likewise the DLCR has some fields which have a lot of 
missing data, namely performance status (17% missing) and stage (19%) although their 
recording of FEV1 is complete in 98% of records.  Even after we had excluded those with 
missing data fields sample sizes remained large and our multiple imputation analysis did not 
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change any of the results substantially suggesting that the missing data did not affect the 
validity of our findings. 
In order to validate Thoracoscore we had to derive two covariates (MRC dyspnoea score and 
ASA grade) as these fields were not available in the NLCA. A sensitivity analysis performed 
using different cut offs to assign ASA grade and MRC dyspnoea score did not change the 
results of the validation so we do not feel that this is an important limitation. ASA grade is 
allocated based on clinician judgement and studies have shown that there is only moderate 
agreement between anaesthetists regarding allocation of a score to an individual(13-15), 
suggesting that even in datasets where this is included, patients with similar co-morbidities 
and functional capacity may be assigned different ASA grades. 
3.9 Comparison with other studies 
A UK study assessed the ability of Thoracoscore to predict mortality following elective lung 
resection in 703 patients (of whom 91% had underlying malignancy). (4) They showed that 
Thoracoscore has limited discriminative and poor predictive ability to determine mortality, 
with area under the ROC value of 0.68 (95% CI 0.56–0.80). They also assessed the 
performance of the revised Thoracoscore (EPITHOR)(16) and the updated European Society 
for Thoracic Surgery mortality score (5) and found poor discriminative ability for both (area 
under ROC 0.61 (95% CI 0.46-0.76) and 0.68 (95% CI 0.54-0.82) respectively.  A second 
publication addressed the ability of Thoracoscore to predict mortality in a population 
undergoing pneumonectomy (largely but not exclusively for underlying malignancy).(17) 
Again the discriminatory power of Thoracoscore in this population was poor with an area 
under the ROC value of 0.44. Both studies suggest that Thoracoscore tends to under-
estimate mortality in those at low-risk and over-estimate risk in high-risk cases.  
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In the previous study by Powell et al(6) three hypothetical patients were used to compare the 
predicted post-operative mortality using Thoracoscore and the NLCA score. This comparison showed 
that the predicted mortality for low risk patients was very similar but mortality in the medium and 
high-risk patients were much higher using the NLCA score (likely reflecting the difference between 
in-hospital and 90 day mortality).  
It is possible that intraoperative factors affect morbidity and mortality. One score comprising 
intraoperative features (the POSSUM score) has been validated in the thoracic surgical population. 
The POSSUM score was originally devised as a tool to facilitate general surgical audit. (18) It consists 
of 12 physiological features (physiologic score (PS)) and an operative severity score (OSS), which 
comprises 6 variables associated with the surgical procedure. Brunelli et al(19) used an Italian cohort 
of 250 lung cancer patients to validate POSSUM as a tool for thoracic surgery. A composite end point 
of morbidity, which included mortality, was used and both models showed only moderate 
discriminative ability (area under ROC curve of 0.66 and 0.67). In order to calculate POSSUM both 
the PS (scored at the time of surgery) and OSS (scored post-operatively) are required to be complete 
which means that this score cannot be used to provide an estimation of pre-operative risk. 
 
3.10 Clinical relevance 
The question is raised regarding what clinicians should use to inform pre-operative 
conversations about surgical risk with patients; by using scoring systems which do not 
predict individual mortality accurately we may be misleading them. In support of this the 
European Respiratory Society/ European Society of Thoracic Surgeons (ERS/ ESTS) (20) reviewed the 
risk scores available to predict post-operative mortality and concluded that current scoring systems 
do not provide an adequate assessment for individual patients. However, they suggest that risk 
scores could be utilised for benchmarking and risk stratification among groups of surgical candidates. 
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Therefore, communicating a range of risk, such as that described in our summary tables 
(tables 2 and 3), taking into account performance status, age and procedure type, may be 
the simplest and most appropriate method of exploring the concept of procedural risk with 
patients. In some ways these are more accessible to patients and surgeons. The population-level 
summary tables we have derived show that, particularly in those patients who are older or who have 
poorer performance status, the range of post-operative mortality is much broader than in the lowest 
risk group, which may explain in part why individual scores have not shown good discriminative 
ability. Individual risk assessment may be possible in the future if improved risk prediction 
models are developed incorporating physiological measurements. Ensuring that risk 
assessment and scoring systems are validated and robust is equally important with the 
proposal that thoracic surgeons should publish surgeon specific outcome data.  
3.11 Conclusions 
These results suggest that although the recently derived NLCA score performs slightly better 
than Thoracoscore in our UK population, neither performs well enough to be advocated for 
routine use prior to lung cancer surgery. It may be that either the addition of physiological 
parameters to demographic and procedural data or risk stratification using physiological 
measurements alone is needed to better predict individual mortality; and this should form 
the basis of further research. In the interim we propose that our summary tables provide 
clinicians and patients with easy-access to the actual range of post-operative mortality in 
the UK for lobectomy and pneumonectomy according to performance status and age. 
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Table 1: Demographics of NLCA and DLCR validation cohorts 
    
NLCA 
cohort   
DLCR 
cohort   
  
 
N=6080 
 
N=4234   
   n % n  % 
Age <55 415 6.83 490 11.6 
  55-65 1660 27.3 1331 31.4 
  66-75 2589 42.58 1643 38.8 
  >75 1416 23.29 770 18.2 
Sex Male 3291 54.13 2155 50.9 
  Female 2789 45.87 2079 49.1 
Performance status 0 2618 43.06 2279 53.8 
  1-2 2624 43.16 1224 28.9 
  ≥3 48 0.79 31 0.7 
  Missing 790 12.99 700 16.5 
% predicted FEV1 >80% 1453 23.9 2413 57 
  61-80% 1064 17.5 1056 24.9 
  40-60% 504 8.29 588 13.9 
  <40% 88 1.45 83 2 
  Missing 2971 48.87 94 2.2 
Procedure type (Bi-)lobectomy, wedge or segmentectomy 5333 87.71 3837 90.6 
  Pneumonectomy 475 7.81 397 9.4 
  Other 475 7.81 - - 
Charlson score 0-1 4020 66.12 3107 73.4 
  ≥2 2060 33.88 1127 26.6 
Stage IA 1747 28.73 1248 29.5 
  IB 1478 24.31 1135 26.8 
  IIA or IIB 1499 24.65 712 16.8 
  IIIA 871 14.33 331 7.8 
  Missing 485 7.98 808 19.1 
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Table 2: Summary table for 30 day mortality for those undergoing lobectomy (Table 2a) and pneumonectomy (Table 2b). 
The 95% confidence intervals are presented in brackets below the risk %, with the total number in this group 
underneath 
Table 2a: 30 day mortality following lobectomy 
  Performance 
status 
 
 
Age (years) 0 1 2 
    
< 70 1% 
(0-1%) 
2534 
2% 
(1-2%) 
1467 
3%  
(1-5%) 
222 
70-80 2% 
(1-3%) 
1361 
3% 
(2-4%) 
1420 
5% 
(2-8%) 
219 
>80 3%  
(1-5%) 
263 
4% 
(2-6%) 
377 
8% 
(2-15%) 
72  
 
Table 2b: 30 day mortality following pneumonectomy 
  Performance 
status 
 
 
Age (years) 0 1 2 
    
< 70 5% 
(3-7%) 
436 
6% 
(3-8%) 
289 
 
- 
70-80 11% 
(6-16%) 
143 
6% 
(3-10%) 
154 
 
- 
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Table 3: Summary table for 90 day mortality for those undergoing lobectomy (Table 3a) and pneumonectomy (Table 3b). 
The 95% confidence intervals are presented in brackets below the risk %, with the total number in each group 
underneath 
Table 3a: 90 day mortality following lobectomy 
  Performance 
status 
 
Age (years) 0 1 2 
    
< 70 2% 
(1-2%) 
2534 
3% 
(2-4%) 
1467 
7% 
(3-10%) 
222 
70-80 4% 
(3-6%) 
1361 
6% 
(5-7%) 
1420 
8% 
(5-12%) 
219 
>80 6% 
(3-9%) 
263 
7% 
(5-10%) 
377 
17% 
(8-25%) 
72 
 
Table 3b: 90 day mortality following pneumonectomy 
  Performance 
status 
 
Age (years) 0 1 2 
    
< 70 7% 
(5-10%) 
436 
12% 
(8-16%) 
289 
 
- 
70-80 18% 
(12-25%) 
143 
12% 
(7-18%) 
154 
 
- 
 
 
